Placebo effects are small on average in the 7.5% CO2 inhalational model of generalised anxiety
Placebo effects are small on average in the 7.5% CO2 inhalational model of generalised anxiety
BACKGROUND: Anxiety disorders are highly prevalent and socio-economically costly. Novel pharmacological treatments for these disorders are needed because many patients do not respond to current agents or experience unwanted side effects. However, a barrier to treatment development is the variable and large placebo response rate seen in trials of novel anxiolytics. Despite this, the mechanisms that drive placebo responses in anxiety disorders have been little investigated, possibly due to low availability of convenient experimental paradigms. We aimed to develop and test a novel protocol for inducing placebo anxiolysis in the 7.5% CO2 inhalational model of generalized anxiety in healthy volunteers.
METHODS: Following a baseline 20-minute CO2 challenge, 32 healthy volunteers were administered a placebo intranasal spray labelled as either the anxiolytic "lorazepam" or "saline." Following this, participants surreptitiously underwent a 20-minute inhalation of normal air. Post-conditioning, a second dose of the placebo was administered, after which participants completed another CO2 challenge.
RESULTS: Participants administered sham "lorazepam" reported significant positive expectations of reduced anxiety (P = .001), but there was no group-level placebo effect on anxiety following CO2 challenge post-conditioning (Ps > .350). Surprisingly, we found many participants exhibited unexpected worsening of anxiety, despite positive expectations.
CONCLUSIONS: Contrary to our hypothesis, our novel paradigm did not induce a placebo response, on average. It is possible that effects of 7.5% CO2 inhalation on prefrontal cortex function or behavior in line with a Bayesian predictive coding framework attenuated the effect of expectations on subsequent placebo response. Future studies are needed to explore these possibilities.
anxiety, Anxiety disorders, placebo effect, placebo response
Huneke, Nathan T.M.
d1be843a-7aab-4978-9b4d-5bcc69b178a7
Cross, Cosmina
883fdd80-0f6a-438b-8352-28d7605afd24
Fagan, Harry A.
e288acbf-f233-4d8e-b304-23cde72dd29e
Molteni, Laura
1b55e314-9610-44cc-95bb-9613be57f375
Phillips, Naomi
eba189b9-55d6-4301-b6d1-9a1c8cf4528b
Garner, Matthew
3221c5b3-b951-4fec-b456-ec449e4ce072
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
30 April 2024
Huneke, Nathan T.M.
d1be843a-7aab-4978-9b4d-5bcc69b178a7
Cross, Cosmina
883fdd80-0f6a-438b-8352-28d7605afd24
Fagan, Harry A.
e288acbf-f233-4d8e-b304-23cde72dd29e
Molteni, Laura
1b55e314-9610-44cc-95bb-9613be57f375
Phillips, Naomi
eba189b9-55d6-4301-b6d1-9a1c8cf4528b
Garner, Matthew
3221c5b3-b951-4fec-b456-ec449e4ce072
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Huneke, Nathan T.M., Cross, Cosmina, Fagan, Harry A., Molteni, Laura, Phillips, Naomi, Garner, Matthew and Baldwin, David S.
(2024)
Placebo effects are small on average in the 7.5% CO2 inhalational model of generalised anxiety.
International Journal of Neuropsychopharmacology, 27 (4), [pyae019].
(doi:10.1093/ijnp/pyae019).
Abstract
BACKGROUND: Anxiety disorders are highly prevalent and socio-economically costly. Novel pharmacological treatments for these disorders are needed because many patients do not respond to current agents or experience unwanted side effects. However, a barrier to treatment development is the variable and large placebo response rate seen in trials of novel anxiolytics. Despite this, the mechanisms that drive placebo responses in anxiety disorders have been little investigated, possibly due to low availability of convenient experimental paradigms. We aimed to develop and test a novel protocol for inducing placebo anxiolysis in the 7.5% CO2 inhalational model of generalized anxiety in healthy volunteers.
METHODS: Following a baseline 20-minute CO2 challenge, 32 healthy volunteers were administered a placebo intranasal spray labelled as either the anxiolytic "lorazepam" or "saline." Following this, participants surreptitiously underwent a 20-minute inhalation of normal air. Post-conditioning, a second dose of the placebo was administered, after which participants completed another CO2 challenge.
RESULTS: Participants administered sham "lorazepam" reported significant positive expectations of reduced anxiety (P = .001), but there was no group-level placebo effect on anxiety following CO2 challenge post-conditioning (Ps > .350). Surprisingly, we found many participants exhibited unexpected worsening of anxiety, despite positive expectations.
CONCLUSIONS: Contrary to our hypothesis, our novel paradigm did not induce a placebo response, on average. It is possible that effects of 7.5% CO2 inhalation on prefrontal cortex function or behavior in line with a Bayesian predictive coding framework attenuated the effect of expectations on subsequent placebo response. Future studies are needed to explore these possibilities.
Text
pyae019
- Accepted Manuscript
Text
pyae019
- Version of Record
More information
Accepted/In Press date: 10 April 2024
Published date: 30 April 2024
Keywords:
anxiety, Anxiety disorders, placebo effect, placebo response
Identifiers
Local EPrints ID: 488969
URI: http://eprints.soton.ac.uk/id/eprint/488969
ISSN: 1461-1457
PURE UUID: 186bab7e-8754-4ac6-8b3d-313e938a585f
Catalogue record
Date deposited: 10 Apr 2024 16:33
Last modified: 03 Sep 2024 01:38
Export record
Altmetrics
Contributors
Author:
Nathan T.M. Huneke
Author:
Cosmina Cross
Author:
Harry A. Fagan
Author:
Laura Molteni
Author:
Naomi Phillips
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics